Share Price and Basic Stock Data
Last Updated: November 20, 2025, 9:24 pm
| PEG Ratio | 4.29 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Anuh Pharma Ltd operates in the pharmaceuticals sector, specializing in manufacturing and marketing pharmaceutical products. As of the latest reporting period, the company’s stock price stood at ₹80.2, with a market capitalization of ₹800 Cr. The revenue trajectory reveals a steady growth pattern, with sales increasing from ₹487 Cr in FY 2022 to ₹662 Cr in FY 2025, reflecting a compound annual growth rate (CAGR) of approximately 10.5%. The trailing twelve months (TTM) revenue recorded is ₹730 Cr, indicating that the company has continued to expand its sales base. Quarterly sales data shows fluctuations, with the highest quarterly sales of ₹172.10 Cr reported in December 2023, underscoring seasonal variations in demand. The company’s operating profit margin (OPM) has shown some volatility, with a peak of 13.94% in December 2023 before declining to 5.52% in June 2025, indicating potential challenges in cost management or pricing pressures in a competitive market.
Profitability and Efficiency Metrics
Anuh Pharma’s profitability metrics exhibit both strengths and challenges. The net profit for FY 2025 was reported at ₹47 Cr, down from ₹60 Cr in FY 2024, leading to a net profit margin of 7.15% in the latest fiscal year. The earnings per share (EPS) for FY 2025 was recorded at ₹4.73, illustrating a decrease from ₹5.99 in FY 2024. The company’s return on equity (ROE) was reported at 14.52%, which remains competitive compared to industry averages, while the return on capital employed (ROCE) stood at 18.78%. The interest coverage ratio (ICR) of 113.62x indicates robust financial health, suggesting that the company generates sufficient earnings to cover interest expenses. However, the operating profit margin (OPM) of 9% for FY 2025 highlights potential inefficiencies, especially when compared to the higher margins previously achieved. Overall, while profitability remains solid, there is a need for improved operational efficiency to sustain growth.
Balance Sheet Strength and Financial Ratios
Anuh Pharma’s balance sheet reflects a strong financial position, characterized by minimal debt and solid liquidity ratios. The total debt to equity ratio is notably low at 0.03, indicating that the company relies primarily on equity financing, which reduces financial risk. The current ratio stands at 2.11, well above the industry norm of 1.5, suggesting that the company is well-positioned to meet its short-term liabilities. The book value per share has increased to ₹65.06 as of March 2025, indicating a strengthening asset base. However, the absence of reserves and borrowings raises questions about the company’s reinvestment strategy and growth funding. Additionally, the price-to-book value (P/BV) ratio of 2.29x suggests that the stock is trading at a premium relative to its book value, which may indicate market confidence but could also suggest overvaluation if earnings do not keep pace with growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Anuh Pharma reveals a stable structure, with promoters holding 71.81% of the company as of September 2025, reflecting significant insider confidence. The public holds 28.19%, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have negligible stakes at 0.00%. The number of shareholders has increased from 19,423 in June 2023 to 28,250 in September 2025, indicating growing retail interest. This increase in shareholder base may enhance liquidity and market interest in the stock. However, the lack of institutional investment could suggest caution from larger investors regarding the company’s growth prospects or market conditions. The dividend payout has decreased from ₹2.50 in FY 2024 to ₹1.50 in FY 2025, which may raise concerns about management’s commitment to returning value to shareholders amidst fluctuating profitability.
Outlook, Risks, and Final Insight
The outlook for Anuh Pharma is mixed, with several growth opportunities alongside notable risks. The company’s strong ROE and low debt levels indicate a solid foundation for future expansion. However, declining profit margins and fluctuating sales indicate operational challenges that must be addressed. The pharmaceutical sector’s competitive landscape may pose risks, particularly in pricing pressures and regulatory hurdles. If the company can enhance its operational efficiency and adapt to market demands, it stands to benefit from the growing healthcare market in India. Conversely, failure to manage costs effectively or innovate could hinder its growth trajectory. Overall, Anuh Pharma’s ability to navigate these challenges while leveraging its strengths will be crucial for sustaining investor confidence and achieving long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Anuh Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,612 Cr. | 423 | 479/192 | 95.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.2 Cr. | 26.1 | 29.1/17.0 | 91.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,228.23 Cr | 1,183.75 | 53.16 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 116.38 | 115.07 | 138.73 | 157.31 | 161.48 | 149.53 | 172.10 | 163.89 | 137.91 | 165.95 | 159.51 | 198.14 | 186.48 |
| Expenses | 105.20 | 101.64 | 126.30 | 143.08 | 147.51 | 131.57 | 148.11 | 144.67 | 127.34 | 149.07 | 144.72 | 179.47 | 176.19 |
| Operating Profit | 11.18 | 13.43 | 12.43 | 14.23 | 13.97 | 17.96 | 23.99 | 19.22 | 10.57 | 16.88 | 14.79 | 18.67 | 10.29 |
| OPM % | 9.61% | 11.67% | 8.96% | 9.05% | 8.65% | 12.01% | 13.94% | 11.73% | 7.66% | 10.17% | 9.27% | 9.42% | 5.52% |
| Other Income | 0.96 | 2.01 | 2.11 | 1.04 | 3.47 | 2.15 | 3.66 | 2.82 | 3.72 | 3.40 | 0.94 | 1.40 | 3.39 |
| Interest | 0.06 | 0.11 | 0.03 | 0.02 | 0.02 | 0.09 | 0.14 | 0.10 | 0.14 | 0.16 | 0.28 | 0.03 | 0.21 |
| Depreciation | 2.42 | 2.44 | 2.43 | 2.41 | 2.01 | 2.15 | 2.20 | 2.23 | 1.88 | 1.92 | 2.18 | 2.76 | 2.52 |
| Profit before tax | 9.66 | 12.89 | 12.08 | 12.84 | 15.41 | 17.87 | 25.31 | 19.71 | 12.27 | 18.20 | 13.27 | 17.28 | 10.95 |
| Tax % | 24.12% | 23.04% | 22.93% | 25.08% | 23.75% | 22.61% | 24.46% | 22.12% | 22.49% | 17.31% | 22.00% | 27.95% | 24.20% |
| Net Profit | 7.34 | 9.92 | 9.31 | 9.62 | 11.75 | 13.83 | 19.11 | 15.36 | 9.51 | 15.04 | 10.34 | 12.46 | 8.30 |
| EPS in Rs | 0.73 | 0.99 | 0.93 | 0.96 | 1.17 | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 |
Last Updated: August 19, 2025, 11:40 pm
Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 186.48 Cr.. The value appears to be declining and may need further review. It has decreased from 198.14 Cr. (Mar 2025) to 186.48 Cr., marking a decrease of 11.66 Cr..
- For Expenses, as of Jun 2025, the value is 176.19 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 179.47 Cr. (Mar 2025) to 176.19 Cr., marking a decrease of 3.28 Cr..
- For Operating Profit, as of Jun 2025, the value is 10.29 Cr.. The value appears to be declining and may need further review. It has decreased from 18.67 Cr. (Mar 2025) to 10.29 Cr., marking a decrease of 8.38 Cr..
- For OPM %, as of Jun 2025, the value is 5.52%. The value appears to be declining and may need further review. It has decreased from 9.42% (Mar 2025) to 5.52%, marking a decrease of 3.90%.
- For Other Income, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.40 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 1.99 Cr..
- For Interest, as of Jun 2025, the value is 0.21 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Mar 2025) to 0.21 Cr., marking an increase of 0.18 Cr..
- For Depreciation, as of Jun 2025, the value is 2.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.76 Cr. (Mar 2025) to 2.52 Cr., marking a decrease of 0.24 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.95 Cr.. The value appears to be declining and may need further review. It has decreased from 17.28 Cr. (Mar 2025) to 10.95 Cr., marking a decrease of 6.33 Cr..
- For Tax %, as of Jun 2025, the value is 24.20%. The value appears to be improving (decreasing) as expected. It has decreased from 27.95% (Mar 2025) to 24.20%, marking a decrease of 3.75%.
- For Net Profit, as of Jun 2025, the value is 8.30 Cr.. The value appears to be declining and may need further review. It has decreased from 12.46 Cr. (Mar 2025) to 8.30 Cr., marking a decrease of 4.16 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.83. The value appears to be declining and may need further review. It has decreased from 1.24 (Mar 2025) to 0.83, marking a decrease of 0.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 730 |
| Expenses | 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 674 |
| Operating Profit | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 56 |
| OPM % | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% |
| Other Income | 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 7 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 10 |
| Profit before tax | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 51 |
| Tax % | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | |
| Net Profit | 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 39 |
| EPS in Rs | 1.76 | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 3.86 |
| Dividend Payout % | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.22% | 18.18% | -23.08% | -15.00% | 35.29% | -39.13% | 100.00% | 10.71% | 16.13% | 66.67% | -21.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -4.04% | -41.26% | 8.08% | 50.29% | -74.42% | 139.13% | -89.29% | 5.41% | 50.54% | -88.33% |
Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | 13% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 2:21 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 |
| Inventory Days | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 |
| Days Payable | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 |
| Cash Conversion Cycle | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 |
| Working Capital Days | 42 | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 |
| ROCE % | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Diluted EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Cash EPS (Rs.) | 11.19 | 13.70 | 9.15 | 8.48 | 8.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Dividend / Share (Rs.) | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 |
| Revenue From Operations / Share (Rs.) | 132.01 | 129.11 | 105.26 | 97.11 | 86.20 |
| PBDIT / Share (Rs.) | 14.04 | 17.41 | 11.45 | 10.39 | 11.00 |
| PBIT / Share (Rs.) | 12.30 | 15.70 | 9.52 | 8.00 | 7.99 |
| PBT / Share (Rs.) | 12.17 | 15.63 | 9.47 | 7.81 | 7.69 |
| Net Profit / Share (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| PBDIT Margin (%) | 10.63 | 13.48 | 10.87 | 10.69 | 12.76 |
| PBIT Margin (%) | 9.31 | 12.15 | 9.04 | 8.23 | 9.27 |
| PBT Margin (%) | 9.22 | 12.10 | 8.99 | 8.03 | 8.92 |
| Net Profit Margin (%) | 7.15 | 9.28 | 6.85 | 6.27 | 6.58 |
| Return on Networth / Equity (%) | 14.52 | 20.62 | 14.99 | 14.29 | 14.91 |
| Return on Capital Employeed (%) | 18.78 | 26.84 | 19.57 | 18.53 | 20.73 |
| Return On Assets (%) | 9.34 | 13.47 | 8.93 | 8.80 | 8.54 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 0.00 | 0.01 | 0.07 |
| Asset Turnover Ratio (%) | 1.39 | 1.52 | 1.40 | 1.43 | 1.31 |
| Current Ratio (X) | 2.11 | 2.20 | 1.91 | 1.98 | 1.70 |
| Quick Ratio (X) | 1.69 | 1.71 | 1.46 | 1.37 | 1.12 |
| Inventory Turnover Ratio (X) | 8.83 | 8.74 | 4.94 | 4.36 | 4.53 |
| Dividend Payout Ratio (NP) (%) | 26.45 | 16.68 | 24.23 | 24.59 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 22.33 | 14.60 | 19.11 | 17.67 | 0.00 |
| Earning Retention Ratio (%) | 73.55 | 83.32 | 75.77 | 75.41 | 0.00 |
| Cash Earning Retention Ratio (%) | 77.67 | 85.40 | 80.89 | 82.33 | 0.00 |
| Interest Coverage Ratio (X) | 113.62 | 246.74 | 262.77 | 54.16 | 36.88 |
| Interest Coverage Ratio (Post Tax) (X) | 77.46 | 170.85 | 166.66 | 32.80 | 20.03 |
| Enterprise Value (Cr.) | 736.68 | 1223.09 | 392.34 | 417.88 | 446.02 |
| EV / Net Operating Revenue (X) | 1.11 | 1.89 | 0.74 | 0.85 | 1.03 |
| EV / EBITDA (X) | 10.47 | 14.02 | 6.84 | 8.03 | 8.09 |
| MarketCap / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| Retention Ratios (%) | 73.54 | 83.31 | 75.76 | 75.40 | 0.00 |
| Price / BV (X) | 2.29 | 4.23 | 1.65 | 2.01 | 2.37 |
| Price / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| EarningsYield | 0.06 | 0.04 | 0.09 | 0.07 | 0.06 |
After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.19. This value is within the healthy range. It has decreased from 13.70 (Mar 24) to 11.19, marking a decrease of 2.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 132.01. It has increased from 129.11 (Mar 24) to 132.01, marking an increase of 2.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 17.41 (Mar 24) to 14.04, marking a decrease of 3.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.30. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.30, marking a decrease of 3.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 15.63 (Mar 24) to 12.17, marking a decrease of 3.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 10.63, marking a decrease of 2.85.
- For PBIT Margin (%), as of Mar 25, the value is 9.31. This value is below the healthy minimum of 10. It has decreased from 12.15 (Mar 24) to 9.31, marking a decrease of 2.84.
- For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 12.10 (Mar 24) to 9.22, marking a decrease of 2.88.
- For Net Profit Margin (%), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 9.28 (Mar 24) to 7.15, marking a decrease of 2.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.52. This value is below the healthy minimum of 15. It has decreased from 20.62 (Mar 24) to 14.52, marking a decrease of 6.10.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has decreased from 26.84 (Mar 24) to 18.78, marking a decrease of 8.06.
- For Return On Assets (%), as of Mar 25, the value is 9.34. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 9.34, marking a decrease of 4.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.52 (Mar 24) to 1.39, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.69, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.83. This value exceeds the healthy maximum of 8. It has increased from 8.74 (Mar 24) to 8.83, marking an increase of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.45. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 26.45, marking an increase of 9.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 22.33. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 22.33, marking an increase of 7.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.55. This value exceeds the healthy maximum of 70. It has decreased from 83.32 (Mar 24) to 73.55, marking a decrease of 9.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 77.67. This value exceeds the healthy maximum of 70. It has decreased from 85.40 (Mar 24) to 77.67, marking a decrease of 7.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 113.62. This value is within the healthy range. It has decreased from 246.74 (Mar 24) to 113.62, marking a decrease of 133.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 77.46. This value is within the healthy range. It has decreased from 170.85 (Mar 24) to 77.46, marking a decrease of 93.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 736.68. It has decreased from 1,223.09 (Mar 24) to 736.68, marking a decrease of 486.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.11, marking a decrease of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 10.47. This value is within the healthy range. It has decreased from 14.02 (Mar 24) to 10.47, marking a decrease of 3.55.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For Retention Ratios (%), as of Mar 25, the value is 73.54. This value exceeds the healthy maximum of 70. It has decreased from 83.31 (Mar 24) to 73.54, marking a decrease of 9.77.
- For Price / BV (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.23 (Mar 24) to 2.29, marking a decrease of 1.94.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
- Net Profit Margin: 7.15%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.78% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.52% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 77.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.7 (Industry average Stock P/E: 43.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.15%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3-A, Shivsagar Estate, Mumbai Maharashtra 400018 | anuh@sk1932.com http://www.anuhpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Todarwal | Chairman & Non-Exe.Director |
| Mr. Bipin N Shah | Vice Chairman & Non Exe.Dire |
| Mr. Ritesh B Shah | Joint Managing Director |
| Mr. Vivek B Shah | Joint Managing Director |
| Mr. Bharat Shah | Non Executive Director |
| Mr. Samir Shah | Non Executive Director |
| Mr. Gaurav S Shah | Non Executive Director |
| Mr. Ketan Shah | Non Executive Director |
| Dr.(Ms.) Mita Dixit | Independent Director |
| Mr. Siddharth J Shah | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
| Mr. Harmanbhai Patel | Independent Director |